Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 28

1.

Rosiglitazone, myocardial ischemic risk, and recent regulatory actions.

Bourg CA, Phillips BB.

Ann Pharmacother. 2012 Feb;46(2):282-9. doi: 10.1345/aph.1Q400. Epub 2012 Jan 31. Review.

PMID:
22298606
[PubMed - indexed for MEDLINE]
2.

Thiazolidinediones in type 2 diabetes: a cardiology perspective.

Khanderia U, Pop-Busui R, Eagle KA.

Ann Pharmacother. 2008 Oct;42(10):1466-74. doi: 10.1345/aph.1K666. Epub 2008 Sep 2. Review.

PMID:
18698014
[PubMed - indexed for MEDLINE]
3.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
[PubMed - indexed for MEDLINE]
4.

Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review.

Wang AT, McCoy CP, Murad MH, Montori VM.

BMJ. 2010 Mar 18;340:c1344. doi: 10.1136/bmj.c1344. Review.

PMID:
20299696
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

The cardiovascular safety of rosiglitazone.

Ajjan RA, Grant PJ.

Expert Opin Drug Saf. 2008 Jul;7(4):367-76. doi: 10.1517/14740338.7.4.367 . Review.

PMID:
18613801
[PubMed - indexed for MEDLINE]
6.

Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation.

Czoski-Murray C, Warren E, Chilcott J, Beverley C, Psyllaki MA, Cowan J.

Health Technol Assess. 2004 Apr;8(13):iii, ix-x, 1-91. Review.

PMID:
15038907
[PubMed - indexed for MEDLINE]
Free Article
7.

The rough road for rosiglitazone.

Goldfine AB.

Curr Opin Endocrinol Diabetes Obes. 2008 Apr;15(2):113-7. doi: 10.1097/MED.0b013e3282f8b483. Review.

PMID:
18316944
[PubMed - indexed for MEDLINE]
8.

Cardiovascular risk of rosiglitazone: another perspective.

Waksman JC.

J Pharm Pharmacol. 2008 Dec;60(12):1573-82. doi: 10.1211/jpp.60.12.0002. Review.

PMID:
19000361
[PubMed - indexed for MEDLINE]
9.

Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies.

Loke YK, Kwok CS, Singh S.

BMJ. 2011 Mar 17;342:d1309. doi: 10.1136/bmj.d1309. Review.

PMID:
21415101
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Safety and efficacy of rosiglitazone in the elderly diabetic patient.

Viljoen A, Sinclair A.

Vasc Health Risk Manag. 2009;5(1):389-95. Review.

PMID:
19475776
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Effects of thiazolidinediones on bone loss and fracture.

Murphy CE, Rodgers PT.

Ann Pharmacother. 2007 Dec;41(12):2014-8. Epub 2007 Oct 16. Review.

PMID:
17940125
[PubMed - indexed for MEDLINE]
12.

Rosiglitazone and pioglitazone for the treatment of Alzheimer's disease.

Miller BW, Willett KC, Desilets AR.

Ann Pharmacother. 2011 Nov;45(11):1416-24. doi: 10.1345/aph.1Q238. Epub 2011 Oct 25. Review.

PMID:
22028424
[PubMed - indexed for MEDLINE]
13.

Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality.

Nissen SE, Wolski K.

Arch Intern Med. 2010 Jul 26;170(14):1191-1201. doi: 10.1001/archinternmed.2010.207. Review.

PMID:
20656674
[PubMed - indexed for MEDLINE]
14.

Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials.

Mannucci E, Monami M, Lamanna C, Gensini GF, Marchionni N.

Diabetes Obes Metab. 2008 Dec;10(12):1221-38. doi: 10.1111/j.1463-1326.2008.00892.x. Epub 2008 May 26. Review.

PMID:
18505403
[PubMed - indexed for MEDLINE]
15.

Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.

Krentz A.

Diabetes Metab Res Rev. 2009 Feb;25(2):112-26. doi: 10.1002/dmrr.937. Review.

PMID:
19219860
[PubMed - indexed for MEDLINE]
16.

Rosiglitazone and cardiovascular risk.

Kaul S, Diamond GA.

Curr Atheroscler Rep. 2008 Oct;10(5):398-404. Review.

PMID:
18706281
[PubMed - indexed for MEDLINE]
17.

The safety of rosiglitazone in the treatment of type 2 diabetes.

Singh S, Loke YK.

Expert Opin Drug Saf. 2008 Sep;7(5):579-85. doi: 10.1517/14740338.7.5.579 . Review.

PMID:
18759710
[PubMed - indexed for MEDLINE]
19.

[Therapy with glitazones--a risk for cardiovascular disease?].

Rottlaender D, Michels G, Erdmann E, Hoppe UC.

Dtsch Med Wochenschr. 2007 Dec;132(49):2629-32. Review. German.

PMID:
18050028
[PubMed - indexed for MEDLINE]
20.

Effectiveness and safety of vitamin D in relation to bone health.

Cranney A, Horsley T, O'Donnell S, Weiler H, Puil L, Ooi D, Atkinson S, Ward L, Moher D, Hanley D, Fang M, Yazdi F, Garritty C, Sampson M, Barrowman N, Tsertsvadze A, Mamaladze V.

Evid Rep Technol Assess (Full Rep). 2007 Aug;(158):1-235. Review.

PMID:
18088161
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk